Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.

Ferrer P, Tello M, Montecinos L, Tordecilla R, Rodríguez C, Beltrán C, Guzmán MA, Ferrés M, Pérez CM, Afani A.

J Clin Virol. 2014 Jul;60(3):290-4. doi: 10.1016/j.jcv.2014.04.004. Epub 2014 Apr 15.

PMID:
24793966
2.

HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.

Ferrer P, Montecinos L, Tello M, Tordecilla R, Rodríguez C, Ferrés M, Pérez CM, Beltrán C, Guzmán MA, Afani A.

Virol J. 2013 Oct 28;10:318. doi: 10.1186/1743-422X-10-318.

3.

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.

PMID:
23412015
4.

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.

DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators.

HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228. Erratum in: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233.

PMID:
22849964
5.

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).

Gotuzzo E, Markowitz M, Ratanasuwan W, Smith G, Prada G, Morales-Ramirez JO, Strohmaier KM, Lu C, Bhanja S, Nguyen BY, Teppler H; Protocol 004 Study Team.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):73-7.

PMID:
22743596
6.

[Prevalence of primary antiretroviral resistance among HIV infected patients in Chile].

Afani A, Beltrán C, María Gallardo A, Roessler P, Acevedo W, Vásquez P.

Rev Med Chil. 2010 Jun;138(6):669-76. Spanish.

PMID:
20919475
7.

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120. Dosage error in article text.

PMID:
20404738
8.

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.

PMID:
19648823
9.

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators.

Lancet. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054. Lancet. 2009 Sep 5;374(9692):786.

PMID:
19647866
10.

[Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)].

Acevedo W, Gallardo AM, Galaz J, Afani A, Cortés E.

Rev Med Chil. 2007 Nov;135(11):1406-13. doi: /S0034-98872007001100006. Epub 2008 Jan 16. Spanish.

11.

[Innate immunity restoration in patients with HIV/AIDS infection associated with antiretroviral therapy].

Afani A, Jiusán L, Raby P, Sitia G, Puente J, Sepúlveda C, Miranda D, Cabrera R, Guidotti L, Lanza P.

Rev Med Chil. 2006 Jun;134(6):689-96. Epub 2006 Aug 14. Spanish.

12.

[Primary resistance to antiretroviral therapy in patients with HIV/AIDS in Chile].

Afani A, Ayala M, Meyer A, Cabrera R, Acevedo W.

Rev Med Chil. 2005 Mar;133(3):295-301. Epub 2005 May 5. Spanish.

13.

[Clinical and immunological study of 10 immunocompetent patients with esophageal candidiasis].

Cortés C, Oksenberg D, Afani A, Defilippi C, Madrid AM.

Rev Med Chil. 2004 Nov;132(11):1389-94. Spanish.

PMID:
15693202
14.

Frequency of CCR5 gene 32-basepair deletion in Chilean HIV-1 infected and non-infected individuals.

Desgranges C, Carvajal P, Afani A, Guzman MA, Sasco A, Sepulveda C.

Immunol Lett. 2001 Mar 1;76(2):115-7.

PMID:
11274729
15.

[Meningitis in subjects with human immunodeficiency virus infection].

Silva-Rosas C, Afani A, Fruns M, Guzmán MA, Sepúlveda C.

Neurologia. 1999 Feb;14(2):62-6. Spanish.

PMID:
10100421
16.

HIV-1 subtypes in Santiago, Chile.

Desgranges C, Fillon S, Letourneur F, Buzelay L, Sepulveda C, Guzman MA, Afani A, Barin F, Saragosti S.

AIDS. 1998 Aug 20;12(12):1563-5. No abstract available.

PMID:
9727586
17.
18.

Behavioral effects of intracerebral administration of luteinizing hormone releasing hormone (LHRH) in rats.

Mora S, Afani A, Kusanovic R, Tapia C, Diaz-Veliz G.

Pharmacol Biochem Behav. 1991 Apr;38(4):705-9.

PMID:
1871186

Supplemental Content

Loading ...
Support Center